Concourse Financial Group Securities, Inc. Next Cure, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.33 - $1.78 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.17 - $2.49 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.13 - $2.23 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.03 - $1.45 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.29 - $1.84 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.29 - $1.84 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.47 - $1.86 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.46 - $1.83 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.2 - $3.07 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.72 - $5.19 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.38 - $5.27 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.76 - $6.24 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.7 - $9.1 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$6.74 - $8.02 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$7.6 - $10.28 $0 - $0
Q1 2021 May 13, 2021	BUY	$9.81 - $13.88 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$9.47 - $12.43 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$8.15 - $21.17 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$21.19 - $40.2 $0 - $0
Q1 2020 May 13, 2020	BUY	$32.32 - $58.37 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$15.73 - $41.6 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$14.16 - $20.64 $0 - $0

Others Institutions Holding NXTC

# of Institutions

Shares Held

15.9M

Call Options Held

Put Options Held

Sofinnova Investments, Inc. Menlo Park, CA

2.67M
Shares

$3.47 Million
0.35% of portfolio
Logos Global Management LP San Francisco, CA

2.5M
Shares

$3.25 Million
0.45% of portfolio
Affinity Asset Advisors, LLC New York, NY

2.3M
Shares

$2.99 Million
0.54% of portfolio
Orbimed Advisors LLC San Diego, CA

1.14M
Shares

$1.48 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

987K
Shares

$1.28 Million
0.0% of portfolio

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.1M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account